[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Soheil Ashkani Esfahani\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100654044","phase-4-suzetrigine-for-postoperative-pain-after-total-ankle-replacement-100654044",false,"NCT07795827","Suzetrigine for Postoperative Pain After Total Ankle Replacement","Project Suzetrigine: The Efficacy and Safety of Suzetrigine (Journavx™) Following Total Ankle Arthroplasty: an Exploratory Prospective Cohort Study","SUZY-TAA","Inclusion Criteria:\n\n* Adult patients aged 18-75 years\n* Undergoing primary total ankle arthroplasty (TAA)\n* Capable of completing study questionnaires\n* Capable of providing informed consent for enrollment\n* Capable of taking suzetrigine twice daily\n* Capable of completing the required follow-up visits\n\nExclusion Criteria:\n\n* Declines to participate or discontinues participation during the study\n* Body mass index (BMI) ≥50 kg\u002Fm²\n* Preoperative or current opioid use\n* Prior history of ipsilateral ankle infection\n* Severe hepatic impairment (Child-Pugh Class C)\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\n* Pregnant or lactating\n* Heart failure or recent myocardial infarction\n* Requires non-antiplatelet anticoagulant therapy (e.g., heparin, warfarin \\[Coumadin\\], apixaban \\[Eliquis\\], or enoxaparin \\[Lovenox\\])\n* Use of strong cytochrome P450 3A (CYP3A) inhibitors (e.g., itraconazole) or strong or moderate CYP3A inducers (e.g., rifampin)\n* Women taking concomitant progestin-containing contraceptives other than levonorgestrel or norethindrone who are unwilling to use an additional non-hormonal contraceptive method (e.g., condoms) or an alternative contraceptive during suzetrigine treatment and for 28 days after discontinuation","ALL","18 Years","75 Years",{"count":21,"type":22},28,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study is testing whether adding a non-opioid pain medicine called suzetrigine (Journavx) to the usual combination of pain medicines helps people recover more comfortably after ankle replacement surgery.\n\nAdults aged 18 to 75 who are scheduled for a first-time total ankle replacement may join. Everyone who joins will receive suzetrigine in addition to their usual pain medicines. Study visits happen at the same times as normal follow-up appointments after surgery.\n\nAt these visits, participants will rate their pain, answer questionnaires about how pain affects daily life, mood, and physical activity, report how much pain medicine they have taken, report any side effects, and have their ankle motion measured.",[28,29,30],"Ankle Osteoarthritis","Postoperative Pain","Acute Pain",[32,33,34,35],"suzetrigine","total ankle arthroplasty","postoperative pain management","foot and ankle surgery","NOT_YET_RECRUITING","2026-09-29",{"date":39,"type":40},"2026-09-30","ACTUAL",{"date":42,"type":22},"2026-10-01",{"date":44,"type":22},"2028-04-01",{"name":46,"class":47},"Soheil Ashkani Esfahani","OTHER",""]